cerebral small vessel disease cognitive impairment
Conditions
Interventions
salvianolic acid A treatment group:salvianolic acid A
Sponsors
Xuanwu Hospital Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.Age 18-80, gender not limited; 2.Changes in memory or other cognitive functions that have been detected or reported by the patient, informant, or physician (i.e., evidence of cognitive decline over time obtained through history or observation), with symptoms lasting at least 3 months.. 3.Based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV), participants do not meet the criteria for cognitive normality or dementia, but their daily living abilities are within the normal range: Mini-Mental State Examination (MMSE) total score >=20 for primary school education or >=24 for middle school education or above, and Montreal Cognitive Assessment (MoCA) total score <= 26. 4.According to STRIVE criteria, participants must have at least one cSVD-related imaging feature on brain MRI, such as lacunes, white matter hyperintensities (WMH), cerebral microbleeds, enlarged perivascular spaces (PVS), or cortical microinfarcts. 5.Participants or their family members must voluntarily agree to participate in this study and sign an informed consent form.
Exclusion criteria
Exclusion criteria: 1.According to the diagnostic criteria from the Intracranial Atherosclerosis Stroke Outcomes and Neuroimaging Study, carotid ultrasound and transcranial Doppler (TCD) indicate vascular stenosis >50% of the luminal diameter causing hemodynamic changes: intracranial internal carotid artery mean flow velocity (MFV) = 2. 5.Cerebral venous damage or lesions. 6.History of intracranial hemorrhage, including intracerebral hemorrhage, ischemic stroke with hemorrhagic transformation, vascular malformation, or intracranial tumors, or active bleeding in other areas. 7.History of brain tumors or psychiatric disorders; history of acute stroke within <= 6 months. 8.Cardiogenic thrombotic diseases, such as mitral stenosis, atrial fibrillation, myocardial infarction within 6 months, cardiac mural thrombus or valvular vegetations, congestive heart failure, or endocarditis. 9.Significant abnormalities in coagulation or bleeding mechanisms. 10.Severe liver or kidney dysfunction, malignancy, or other serious illnesses requiring medical or surgical intervention. 11.Pregnant or breastfeeding women. 12.Expected survival <6 months. 13.Refusal to sign informed consent, poor compliance, or inability to complete the full treatment regimen.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| p-CASL perfusion at 3 months; | — |
Secondary
| Measure | Time frame |
|---|---|
| Neuropsychological function;Imaging biomarkers of cerebral small vessel disease;Any adverse event;Laboratory indicators;Hemodynamics; | — |
Countries
China
Contacts
Public ContactHaiqing Song
Xuanwu Hospital Capital Medical University
Outcome results
None listed